The 'cytokine profile': A code for sepsis

Trends in Molecular Medicine

Volumn 11, Issue 2, 2005, Pages 56-63

  Ulloa, Luis ^a   Tracey, Kevin J ^a  

^a North Shore LIJ Research Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTIINFECTIVE AGENT; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; NEUTRALIZING ANTIBODY; NICOTINE; PYRUVIC ACID ETHYL ESTER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BODY TEMPERATURE; BREATHING RATE; CAUSE OF DEATH; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; GENETICS; HEART RATE; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INNATE IMMUNITY; LEUKOCYTE COUNT; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL;

BACTERIA (MICROORGANISMS);

EID: 13244288781     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.12.007     Document Type: Article

References (65)

1. K.E. Sands Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group J. Am. Med. Assoc. 278 1997 234 240
2. D.C. Angus Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit. Care Med. 29 2001 1303 1310
3. G.S. Martin The epidemiology of sepsis in the United States from 1979 through 2000 N. Engl. J. Med. 348 2003 1546 1554
4. G. Friedman Has the mortality of septic shock changed with time Crit. Care Med. 26 1998 2078 2086
5. L. Ulloa Inhibition of TGFβ/SMAD signal transduction by the INFγ/STAT pathway Nature 397 1999 710 712
6. G. Monteleone Smad7 in TGFβ mediated negative regulation of gut inflammation Trends Immunol. 25 2004 513 517
7. K. Miyazono Coordinate regulation of cell growth and proliferation by TGFβ superfamily and Tunx proteins Oncogene 23 2004 4232 4237
8. R.S. Hotchkiss, and I.E. Karl The pathophysiology and treatment of sepsis N. Engl. J. Med. 348 2003 138 150
9. K.J. Tracey, and A. Cerami Tumor necrosis factor: a pleiotropic cytokine and therapeutic target Annu. Rev. Med. 45 1994 491 503
10. K.J. Tracey, and A. Cerami Tumor necrosis factor, other cytokines and disease Annu. Rev. Cell Biol. 9 1993 317 343
11. K.J. Tracey Shock and tissue injury induced by recombinant human cachectin Science 234 1986 470 474
12. K.J. Tracey Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia Nature 330 1987 662 664
13. C.A. Dinarello The interleukin-1 family: 10 years of discovery FASEB J. 8 1994 1314 1325
14. J.C. Marshall Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome Crit. Care Med. 23 1995 1638 1652
15. N.C. Riedemann Novel strategies for the treatment of sepsis Nat. Med. 9 2003 517 524
16. E. Abraham HMG-1 as a mediator of acute lung inflammation J. Immunol. 165 2000 2950 2954
17. T. Van der Poll, and S.F. Lowry Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 3 1995 1 12
18. M. Feldmann Development of anti-TNF therapy for rheumatoid arthritis Nat. Rev. Immunol. 2 2002 364 371
19. G. Van Assche, and P. Rutgeerts Anti-TNF agents in Crohn's disease Expert Opin. Investig. Drugs 9 2000 103 111
20. E. Abraham Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Norasept ii study group Lancet 351 1998 929 933
21. E. Abraham Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase iii trial with 1,342 patients Crit. Care Med. 29 2001 503 510
22. C.J. Fisher Jr Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial J. Am. Med. Assoc. 271 1994 1836 1843
23. E. Abraham Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: a reevaluation Crit. Care Med. 28 2000 232 235
24. I. Matot, and C.L. Sprung Definition of sepsis Intensive Care Med. 27 2001 S3 S9
25. G.R. Bernard Efficacy and safety of recombinant human activated protein C for severe sepsis N. Engl. J. Med. 344 2001 699 709
26. H. Wang Lipid unites disparate syndromes of sepsis Nat. Med. 10 2004 124 125
27. C.J. Czura HMGB1 in the immunology of sepsis (not septic shock) and arthritis Adv. Immunol. 84 2004 181 200
28. P. Brandtzaeg, and M. van Deuren Current concepts in the role of the host response in Neisseria meningitidis septic shock Curr. Opin. Infect. Dis. 15 2002 247 252
29. V. Kindler The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection Cell 56 1989 731 740
30. M.K. Eskandari Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia J. Immunol. 148 1992 2724 2730
31. D. Remick Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture Shock 4 1995 89 95
32. H. Wang Hmg-1 as a late mediator of endotoxin lethality in mice Science 285 1999 248 251
33. H. Yang Reversing established sepsis with antagonists of endogenous high-mobility group box 1 Proc. Natl. Acad. Sci. U. S. A. 101 2004 296 301
34. U. Andersson High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes J. Exp. Med. 192 2000 565 570
35. P.L. Sappington Hmgb1 b box increases the permeability of caco-2 enterocytic monolayers and impairs intestinal barrier function in mice Gastroenterology 123 2002 790 802
36. B. Degryse The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells J. Cell Biol. 152 2001 1197 1206
37. J. Li Recombinant HMGB1 with cytokine-stimulating activity J. Immunol. Methods 289 2004 211 223
38. C.J. Czura High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor J. Infect. Dis. 187 2003 S391 S396
39. C.C. Baker Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model Surgery 94 1983 331 335
40. M. Ombrellino Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock Lancet 354 1999 1446 1447
41. L. Ulloa Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation Proc. Natl. Acad. Sci. U. S. A. 99 2002 12351 12356
42. L. Ulloa Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release Ann. N. Y. Acad. Sci. 987 2003 319 321
43. M.P. Fink Ethyl pyruvate: a novel treatment for sepsis and shock Minerva Anestesiol. 70 2004 365 371
44. H. Wang Cholinergic agonists Inhibits HMGB1 Release and Improve Survival in Experimental Sepsis Nat. Med. 10 2004 1216 1220
45. M.A. Matthay, and L.B. Ware Can nicotine treat sepsis? Nat. Med. 10 2004 1261 1262
46. H. Wang Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation Nature 421 2003 384 388
47. W.H. Fang The significance of changes in high mobility group-1 protein mRNA expression in rats after thermal injury Shock 17 2002 329 333
48. R. Kokkola High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis Arthritis Rheum. 46 2002 2598 2603
49. L. Ulloa High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis Arthritis Rheum. 48 2003 876 881
50. M. Bustin At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1 Sci STKE 151 2002 39 43
51. P. Scaffidi Release of chromatin protein hmgb1 by necrotic cells triggers inflammation Nature 418 2002 191 195
52. J.H. Morse Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone Clin. Exp. Immunol. 106 1996 389 395
53. F. Jung Antibodies against a peptide sequence located in the linker region of the HMG-1/2 box domains in sera from patients with juvenile rheumatoid arthritis Arthritis Rheum. 40 1997 1803 1809
54. L.M. Ayer Antibodies to high mobility group proteins in systemic sclerosis J. Rheumatol. 21 1994 2071 2075
55. M. Bustin Autoantibodies to nucleosomal proteins: antibodies to HMG-17 in autoimmune diseases Science 215 1982 1245 1247
56. T. Calandra Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock J. Infect. Dis. 161 1990 982 987
57. J.D. Marks Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration Am. Rev. Respir. Dis. 141 1990 94 97
58. J.H. Kabarowski Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A Science 293 2001 702 705
59. R.S. Hotchkiss Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte Nat. Immunol. 1 2000 496 501
60. + T lymphocytes in humans J. Immunol. 166 2001 6952 6963
61. M. Saleh Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms Nature 429 2004 75 79
62. D.W. Nicholson Caspase structure, proteolytic substrates, and function during apoptotic cell death Cell Death Differ. 6 1999 1028 1042
63. M. Lamkanfi Alice in caspase land. A phylogenetic analysis of caspases from worm to man Cell Death Differ. 9 2002 358 361
64. F. Martinon, and J. Tschopp Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases Cell 117 2004 561 574
65. E.M. Creagh Caspase-activation pathways in apoptosis and immunity Immunol. Rev. 193 2003 10 21